KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Alnylam Pharmaceuticals (ALNY) Short term Debt (2024 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Short term Debt for 2 consecutive years, with $121.3 million as the latest value for Q3 2025.

For Q3 2025, Short term Debt changed N/A year-over-year to $121.3 million; the TTM value through Sep 2025 reached $121.3 million, changed N/A, while the annual FY2024 figure was $93.8 million, N/A changed from the prior year.
Short term Debt hit $121.3 million in Q3 2025 for Alnylam Pharmaceuticals, roughly flat from $120.8 million in the prior quarter.
Across five years, Short term Debt topped out at $121.3 million in Q3 2025 and bottomed at $93.8 million in Q4 2024.